RECRUITINGPhase 2INTERVENTIONAL
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
About This Trial
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Who May Be Eligible (Plain English)
Who May Qualify:
- Fully understand the study and voluntarily sign the willing to sign a consent form form.
- 18-75 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
- Life expectancy ≥ 12 weeks.
Who Should NOT Join This Trial:
- Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Fully understand the study and voluntarily sign the informed consent form.
* 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
* Life expectancy ≥ 12 weeks.
Exclusion Criteria:
* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Treatments Being Tested
BIOLOGICAL
ZG005 for Injection
10 mg/kg or 20 mg/kg administered intravenously Q3w
BIOLOGICAL
Bevacizumab
15 mg/kg administered intravenously Q3w
BIOLOGICAL
Sintilimab
200 mg administered intravenously Q3w
BIOLOGICAL
Bevacizumab
15 mg/kg administered intravenously Q3w
Locations (1)
West China Hospital of Sichuan University
Chengdu, Sichuan, China